Percentage (%) of microscopically verified cases (persons)
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All invasive xnmsc | 81.0% | 80.8% | 81.2% | 79.2% | 83.4% | 79.6% |
| All xnmsc 0-24 | 91.6% | 92.1% | 91.4% | 96.1% | 92.6% | 88.4% |
| All xnmsc 25-59 | 94.9% | 95.7% | 94.7% | 95.7% | 97.1% | 95.2% |
| All xnmsc 60-79 | 85.4% | 85.0% | 85.6% | 83.2% | 87.3% | 83.9% |
| All xnmsc 80+ | 56.3% | 54.8% | 56.9% | 51.1% | 57.1% | 54.2% |
| All registrations | 86.4% | 86.2% | 86.5% | 85.4% | 86.9% | 86.0% |
| Haematology | 83.5% | 88.9% | 82.2% | 92.8% | 92.4% | 88.3% |
| Head and Neck | 96.1% | 96.0% | 96.1% | 96.4% | 95.4% | 96.1% |
| Lower GI | 84.7% | 84.7% | 84.9% | 82.0% | 87.8% | 84.1% |
| Upper GI | 88.7% | 89.0% | 88.8% | 87.7% | 92.8% | 86.8% |
| HPB | 49.2% | 48.2% | 50.1% | 41.0% | 59.2% | 42.4% |
| Trachea, Bronchus & Lung | 63.5% | 62.1% | 64.2% | 58.6% | 62.6% | 62.9% |
| Melanoma of skin | 99.3% | 99.3% | 99.3% | 99.9% | 98.8% | 99.1% |
| Breast | 97.6% | 98.0% | 97.5% | 98.2% | 98.5% | 97.6% |
| Cervix | 97.1% | 97.5% | 97.0% | 98.1% | 98.6% | 96.2% |
| Other Female Genitals | 92.7% | 91.9% | 93.0% | 91.4% | 91.5% | 91.5% |
| Prostate | 82.4% | 82.6% | 82.5% | 81.4% | 83.8% | 82.6% |
| Kidney | 67.2% | 69.4% | 66.6% | 70.4% | 72.3% | 68.1% |
| Bladder | 85.5% | 86.3% | 85.4% | 84.6% | 89.0% | 86.3% |
| Brain and CNS | 63.9% | 58.3% | 65.1% | 66.4% | 55.7% | 45.9% |
| Thyroid & other endocrine glands | 95.8% | 96.2% | 95.6% | 97.1% | 99.4% | 92.7% |
| CUP | 37.6% | 39.1% | 37.6% | 38.3% | 46.4% | 34.0% |
| Other invasive cancer | 82.1% | 79.9% | 83.3% | 72.4% | 86.8% | 77.0% |
| Breast in situ | 99.9% | 100.0% | 99.9% | 100.0% | 100.0% | 100.0% |
| Cervix in situ | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Other tumours | 85.1% | 84.4% | 84.8% | 90.7% | 81.1% | 81.2% |
Percentage (%) of non-specificity of morphology codes for cases which are microscopically verified
| Country average (population) | Country average (country) | England | Scotland | Northern Ireland | Wales | |
|---|---|---|---|---|---|---|
| All xnmsc 0-24 | 1.2% | 0.4% | 1.4% | 0.0% | 0.0% | 0.0% |
| All xnmsc 25-59 | 1.0% | 0.8% | 1.0% | 0.6% | 0.8% | 0.7% |
| All xnmsc 60-79 | 1.2% | 1.0% | 1.3% | 0.8% | 1.2% | 0.8% |
| All xnmsc 80+ | 2.6% | 2.0% | 2.7% | 1.6% | 2.1% | 1.6% |
| All registrations | 1.1% | 0.9% | 1.1% | 0.6% | 1.4% | 0.6% |
| Haematology | 0.5% | 0.4% | 0.5% | 0.4% | 0.3% | 0.5% |
| Head and Neck | 0.9% | 0.8% | 0.9% | 0.9% | 1.4% | 0.2% |
| Lower GI | 1.1% | 0.7% | 1.2% | 0.4% | 0.6% | 0.8% |
| Upper GI | 1.1% | 0.9% | 1.2% | 0.7% | 0.6% | 1.0% |
| HPB | 5.5% | 4.5% | 5.8% | 4.3% | 4.3% | 3.7% |
| Trachea, Bronchus & Lung | 2.3% | 1.7% | 2.5% | 1.6% | 1.6% | 1.2% |
| Melanoma of skin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Breast | 1.2% | 1.2% | 1.2% | 0.5% | 1.9% | 1.1% |
| Cervix | 0.8% | 0.3% | 0.9% | 0.4% | 0.0% | 0.0% |
| Other Female Genitals | 1.0% | 0.5% | 1.2% | 0.6% | 0.0% | 0.1% |
| Prostate | 0.7% | 0.3% | 0.8% | 0.1% | 0.0% | 0.5% |
| Kidney | 1.5% | 0.7% | 1.7% | 0.8% | 0.0% | 0.2% |
| Bladder | 1.0% | 0.7% | 1.1% | 0.3% | 1.0% | 0.5% |
| Brain and CNS | 1.2% | 0.3% | 1.4% | 0.0% | 0.0% | 0.0% |
| Thyroid & other endocrine glands | 1.8% | 1.1% | 2.0% | 0.8% | 0.6% | 1.0% |
| CUP | 15.1% | 15.4% | 15.5% | 13.7% | 23.8% | 8.4% |
| Other invasive cancer | 0.9% | 0.9% | 0.9% | 0.6% | 1.2% | 0.7% |
| Breast in situ | 0.2% | 0.2% | 0.2% | 0.0% | 0.5% | 0.0% |
| Cervix in situ | 1.2% | 0.4% | 1.4% | 0.0% | 0.0% | 0.0% |
| Other tumours | 2.1% | 2.2% | 2.1% | 1.1% | 5.0% | 0.8% |